Radiopharm Theranostics plans to raise approximately $10 million through a non-renounceable entitlement offer, with a proposed offer price of 7 Australian cents per new share.
The offer allows eligible shareholders to subscribe to one new ordinary share for every 2.35 existing shares.
The company aims to utilise the funds for advancing multiple clinical trials, bolstering working capital, and covering the costs of the offer.
The entitlement offer is set to open on Nov. 8 and close on Nov. 24. A top-up facility will be available for eligible shareholders who fully take up their entitlements.